Filtration System
Sartorius Stedim Biotech has developed SARTOFLOW Alpha plus, a flexible modular benchtop crossflow filtration system, which provides semi-automatic micro-, ultra-, and diafiltration, and is especially suited for process development, clinical testing, and smaller production processes.
Sartorius Stedim Biotech has developed SARTOFLOW Alpha plus, a flexible modular benchtop crossflow filtration system, which provides semi-automatic micro-, ultra-, and diafiltration, and is especially suited for process development, clinical testing, and smaller production processes. Because of its standardized options, the system can be adapted to the changing production demands of downstream processing. The steaming-in-place module for thermal sterilization gives users the option to run all cross flow processes aseptically. The SARTOFLOW Alpha plus system is cGMP-compliant and self-draining. The system operates with either disposable bag technology or permanently installed tank. The cross-flow system is equipped with a DCU4 control module, which allows communication with the SCADA MFCS/WIN data logging and control software from Sartorius Stedim Biotech and makes integration with existing networks effortless.
www.sartorius-stedim.com.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
